Download PDF
Klin Monbl Augenheilkd 2022; 239(04): 435-442
DOI: 10.1055/a-1766-7320
Klinische Studie

Two-Year Outcome of Surgery in Glaucoma Patients

Outcome nach Chirurgie bei Glaukompatienten nach 2 Jahren
Roger Hüppi
1   Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
,
Barbara Wagels
1   Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
,
Margarita Todorova
1   Department of Ophthalmology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
2   Department of Ophthalmology, University of Basel, Basel, Switzerland
3   University of Zürich, Zürich, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Purpose To evaluate the 2-year surgical treatment outcome in glaucoma patients.

Methods A retrospective, single-center, interventional study was performed on 160 eyes of 125 patients suffering glaucoma, including POAG (82 eyes), pseudoexfoliation (PEX) (59 eyes), pigment dispersion (8 eyes), and secondary glaucoma (2 eyes). Eyes with uncontrolled intraocular pressure (IOP) or signs of glaucoma progression despite medical treatment were included to undergo either trabeculectomy (TE), XEN implantation, combined TE with phacoemulsification (TE + IOL), or XEN implantation with phacoemulsification surgery (XEN + IOL). Primary efficacy outcome was the mean IOP reduction. Secondary outcome was the mean reduction in the number of medications. The data were compared at baseline vs.1 day, 1 week, and 1, 3, 6, 12, and 24 months following surgery. For statistical evaluation, ANOVA-based linear mixed-effects models were performed with SPSS.

Results The mean IOP reduction in a 2-year follow-up was 30.31% (22.17 vs. 15.45 mmHg, p < 0.001). The mean number of antiglaucoma medications was reduced from 2.87 to 0.58 (p = 0.001), where TE alone or combined surgeries seemed to be more effective than isolated XEN surgery. Transient IOP hypotony on the first postoperative day occurred in PEX patients following TE surgery (p = 0.024). At 6 months, PEX patients with isolated XEN surgery showed a transient IOP increase, whereas those after combined TE + IOL surgery showed the lowest IOP within the PEX group compared to other glaucoma patients (p < 0.026).

Conclusions After 2 years, all performed glaucoma surgeries achieved a significant reduction in IOP and the number of antiglaucoma medications.

Zusammenfassung

Absicht Evaluierung des Outcomes in den ersten 2 Jahren nach Chirurgie bei Glaukompatienten.

Methoden Eine retrospektive, Single-Center-Studie wurde bei 160 Augen von 125 Glaukompatienten durchgeführt, miteingeschlossen: POWG (82 Augen), PEX (59 Augen), Pigmentdispersion (8 Augen) und Sekundärglaukom (2 Augen). Augen mit dekompensiertem Intraokulardruck (IOD) oder Zeichen einer Glaukomprogression trotz medikamentöser Therapie wurden eingeschlossen, um sich einer Trabekulektomie (TE), XEN-Implantation, kombinierter TE mit Phakoemulsifikation (Phaco-TE) oder XEN-Implantation mit Phakoemulsifikation (Phaco-XEN) zu unterziehen. Der primäre Wirksamkeitsendpunkt war die mittlere Reduktion des IODs. Sekundär wurde das Outcome der Reduktion der Anzahl Medikamentenwirkstoffe überprüft. Die Daten wurden verglichen zwischen präoperativen Werten und 1. Tag, 1. Woche, 1., 3., 6., 12. und 24. Monat postoperativ nach Glaukomchirurgie. Für die statistische Evaluation wurden ANOVA-basierte lineare, gemischte Modelle verwendet, erzeugt mit SPSS.

Resultate Die mittlere IOD-Reduktion nach 2 Jahren war 30,31% (22,17 zu 15,45 mmHg, p < 0,001). Die mittlere Anzahl der antiglaukomatösen Medikamente wurde von 2,87 auf 0,58 (p = 0,001) reduziert, wobei die TE und Phaco-TE einen Trend zur besseren Effektivität als die isolierte XEN-Implantation zeigen. Transiente IOD-Hypotonie am 1. postoperativen Tag traten bei PEX-Patienten nach TE-Chirurgie auf (p = 0,024). Nach 6 Monaten zeigten PEX-Patienten nach isolierter XEN-Implantation einen transienten IOD-Anstieg, wogegen jene nach Phaco-TE den niedrigsten IOD sowohl in der PEX-Gruppe als auch verglichen mit anderen Glaukompatienten zeigten (p < 0,026).

Schlussfolgerungen Nach 2 Jahren zeigte sich in allen durchgeführten glaukomchirurgischen Eingriffen eine signifikante Reduktion des IODs und der Reduktion der Anzahl Glaukommedikamente.

Key words

glaucoma - surgery - minimally invasive glaucoma surgery - trabeculectomy - XEN

Schlüsselwörter

Glaukom - Chirurgie - minimalinvasive Glaukomchirurgie - Trabekulektomie - XEN


Publication History

Received: 10 October 2021

Accepted: 06 February 2022

Article published online:
23 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Resnikoff S, Pascolini D, Etyaʼale D. et al. Global data on visual impairment in the year 2002. Community Eye Health 2004; 17: 61
    PubMedGoogle Scholar
  • 2 Tham YC, Li X, Wong TY. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081-2090
    CrossrefPubMedGoogle Scholar
  • 3 Lichter PR, Musch DC, Gillespie BW. et al. CIGTS Study Group Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943-1953
    CrossrefPubMedGoogle Scholar
  • 4 Feiner L, Piltz-Seymour JR. Collaborative Initial Glaucoma Treatment Study. Collaborative Initial Glaucoma Treatment Study: A summary of results to date. Curr Opin Ophthalmol 2003; 14: 06-11
    CrossrefPubMedGoogle Scholar
  • 5 Reitsamer H, Sng C, Vera V. et al. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2019; 257: 983-996
    CrossrefPubMedGoogle Scholar
  • 6 Sheybani A, Reitsamer H, Ahmed II. Fluid Dynamics of a Novel Micro-Fistula Implant for the Surgical Treatment of Glaucoma. Invest Ophthalmol Vis Sci 2015; 56: 4789-4795
    CrossrefPubMedGoogle Scholar
  • 7 Gedde SJ, Heuer DK, Parrish RK. Tube Versus Trabeculectomy Study Group: Review of results from the Tube Versus Trabeculectomy Study. Curr Opin Ophthalmol 2010; 21: 123-128
    CrossrefPubMedGoogle Scholar
  • 8 Birnbaum FA, Neeson C, Solá-Del Valle D. Microinvasive Glaucoma Surgery: An Evidence-Based Review. Semin Ophthalmol 2021; 36: 772-786
    CrossrefPubMedGoogle Scholar
  • 9 Sadruddin O, Pinchuk L, Angeles R. et al. Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: a review. Eye Vis (Lond) 2019; 6: 36
    CrossrefPubMedGoogle Scholar
  • 10 Manasses DT, Au L. The New Era of Glaucoma Micro-stent Surgery. Ophthalmol Ther 2016; 5: 135-146
    CrossrefPubMedGoogle Scholar
  • 11 Sheheitli H, Tirpack AR, Parrish RK. Which Patients Would Most Likely to Benefit: MIGS or MEGS, Which One Is It?. Asia Pac J Ophthalmol (Phila) 2019; 8: 436-440
    CrossrefPubMedGoogle Scholar
  • 12 Grover DS, Flynn WJ, Bashford KP. et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol 2017; 183: 25-36
    CrossrefPubMedGoogle Scholar
  • 13 Wanichwecharungruang B, Ratprasatporn N. 24-month outcomes of XEN45 gel implant versus trabeculectomy in primary glaucoma. PLoS One 2021; 16: e0256362
    CrossrefPubMedGoogle Scholar
  • 14 Schlenker MB, Ong JA, Wu P. et al. Surgeon Experience as a Risk Factor for Short-Term Failure for Ab Interno Gelatin Microstent: A Canadian Multicenter Propensity-Matched Study. Ophthalmol Glaucoma 2022; 5: 67-76
    CrossrefPubMedGoogle Scholar
  • 15 Lenzhofer M, Kersten-Gomez I, Sheybani A. et al. Four-year results of a minimally invasive transscleral glaucoma gel stent implantation in a prospective multi-centre study. Clin Exp Ophthalmol 2019; 47: 581-587
    CrossrefPubMedGoogle Scholar
  • 16 Lavin-Dapena C, Cordero-Ros R, DʼAnna O. et al. XEN 63 gel stent device in glaucoma surgery: A 5-years follow-up prospective study. Eur J Ophthalmol 2021; 31: 1829-1835
    CrossrefPubMedGoogle Scholar
  • 17 Rauchegger T, Angermann R, Willeit P. et al. Two-year outcomes of minimally invasive XEN Gel Stent implantation in primary open-angle and pseudoexfoliation glaucoma. Acta Ophthalmol 2021; 99: 369-375
    CrossrefPubMedGoogle Scholar
  • 18 Schargus M, Theilig T, Rehak M. et al. Outcome of a single XEN microstent implant for glaucoma patients with different types of glaucoma. BMC Ophthalmol 2020; 20: 490
    CrossrefPubMedGoogle Scholar
  • 19 Topouzis F, Wilson MR, Harris A. et al. Risk factors for primary open-angle glaucoma and pseudoexfoliative glaucoma in the Thessaloniki eye study. Am J Ophthalmol 2011; 152: 219-228.e1
    CrossrefPubMedGoogle Scholar
  • 20 Schlötzer-Schrehardt U. [New pathogenetic insights into pseudoexfoliation syndrome/glaucoma. Therapeutically relevant?]. Ophthalmologe 2012; 109: 944-951
    CrossrefPubMedGoogle Scholar
  • 21 Friedman DS, Jampel HD, Lubomski LH. et al. Surgical strategies for coexisting glaucoma and cataract: an evidence-based update. Ophthalmology 2002; 109: 1902-1913
    CrossrefPubMedGoogle Scholar
  • 22 Ahmadzadeh A, Kessel L, Subhi Y. et al. Comparative Efficacy of Phacotrabeculectomy versus Trabeculectomy with or without Later Phacoemulsification: A Systematic Review with Meta-Analyses. J Ophthalmol 2021; 2021: 6682534
    CrossrefPubMedGoogle Scholar
  • 23 Hengerer FH, Kohnen T, Mueller M. et al. Ab interno gel implant for the treatment of glaucoma patients with or without prior glaucoma surgery: 1-year results. J Glaucoma 2017; 26: 1130-1136
    CrossrefPubMedGoogle Scholar
  • 24 Tan SZ, Walkden A, Au L. One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management. Eye (Lond) 2018; 32: 324-332
    CrossrefPubMedGoogle Scholar
  • 25 Ibáñez-Muñoz A, Soto-Biforcos VS, Chacón-González M. et al. One-year follow-up of the XEN® implant with mitomycin-C in pseudoexfoliative glaucoma patients. Eur J Ophthalmol 2019; 29: 309-314
    CrossrefPubMedGoogle Scholar
  • 26 Schlenker MB, Gulamhusein H. Conrad-Hengerer. et al. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy. Ophthalmology 2017; 124: 1579-1588
    CrossrefPubMedGoogle Scholar